This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
PRODIGE 23 was a phase 3 randomized parallel-group treatment trial evaluating neoadjuvant mFolfirinox in patients with resectable locally advanced rectal cancer.
| Feature | Description |
|---|---|
| Condition | Cancer of the Rectum |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | UNICANCER |
2. Clinical Question
Population
Patients with resectable locally advanced rectal cancer.
Intervention
mFolfirinox with additional trial-specified treatment components including radiotherapy, capecitabine, and TME surgery.
Comparator
The control treatment pathway included mFolfox6 or capecitabine.
Primary question
Does the investigational strategy improve 3-year disease-free survival compared with the control arm?
3. Trial Design
461 patients
2 groups
Protocol therapy
TME
Disease-free survival
Investigational strategy
- mFolfirinox
- Radiotherapy 50 Gy
- Capecitabine
- TME surgery
Control strategy
- mFolfox6 or capecitabine
- Radiotherapy 50 Gy
- TME surgery
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Disease-free survival | To compare the 3-year disease-free survival between the investigational arm and the control arm. | 3 years |
5. Planned Analysis
The ClinicalTrials.gov record identifies disease-free survival as the primary endpoint. Disease-free survival is a time-to-event endpoint generally evaluated using methods such as Kaplan-Meier estimation, comparison of survival curves, and regression approaches that estimate relative treatment effects.
6. Statistical Methodology
Time-to-event analysis
Disease-free survival measures the time until a defined disease-related event or censoring. Statistical methods for this endpoint account for patients who have different follow-up durations.
S(t) represents the probability that an individual remains event-free beyond time t.
Randomization
The randomized allocation creates the framework for comparing treatment strategies while reducing the influence of measured and unmeasured baseline differences between groups.
7. Statistical Methods Explained
Why is disease-free survival used as the primary endpoint?
Disease-free survival combines information about recurrence-related events and follow-up time. It can provide an earlier assessment of treatment effects than overall survival in some cancer trials.
Why does randomization matter?
Randomization allows treatment groups to be compared according to their assigned intervention rather than according to characteristics that may influence outcomes.
How is a time-to-event endpoint analyzed?
Patients are followed over time, and observations without the event by the end of follow-up contribute information through censoring methods.
Why are confidence intervals important?
A confidence interval describes uncertainty around an estimated treatment effect. It does not describe the range of outcomes experienced by individual patients.
Why can a registry endpoint description not replace a statistical analysis?
An endpoint definition explains what will be measured, but interpretation requires the reported estimates, uncertainty measures, and statistical testing results.
8. Limitations
- The registry does not report posted statistical analyses for the primary endpoint.
- Numerical treatment-effect estimates and confidence intervals are not available in the ClinicalTrials.gov record.
- The registry description does not provide additional details regarding interim analyses, multiplicity adjustment, missing-data methods, or subgroup analyses.
9. Why This Trial Matters Statistically
PRODIGE 23 is an example of a randomized phase 3 oncology trial where the statistical framework centers on a time-to-event endpoint. The design illustrates how randomized comparisons, endpoint definitions, and survival-analysis methods work together in evaluating treatment strategies.
| Concept | Application |
|---|---|
| Randomization | Parallel randomized comparison |
| Primary endpoint | 3-year disease-free survival |
| Time-to-event methods | Appropriate framework for disease-free survival analysis |
| Interpretation | Requires both effect estimates and uncertainty measures |